Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (9682)	6/15/1998 9:43:00 PM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 23519

Edderd,I think the " Viagra Fireworks " overseas will start very soon: as you may already know, coronary artery disease care overseas is pitiful; -only the well-heeled, " may ", get a by pass ( if they are still alive that is after years of symptoms ). -in UK, bypasses are not given after age 55 ( DaiS may want to correct this ). So that the bottom line is that UNDIAGNOSED coronary artery disease is rampant.As soon these calcified coronaries receive their " Viagra sex test ", they will fail, in thousands. They may pop a nitroglycerine, if they are poorly informed; or they may get a nitro in the ambulance or the ER. It will be interesting to see what happens when their tabloids get hold of this. When their government sees it ( as well as the cost of treating all this newly discovered coronary artery disease ), I am looking to see significant restrictions in sales. Again, remember the old principle: Three quarters of all deaths in men are due to coronary artery disease. You don't have to answer if you agree. I am just being my usual "nice guy ", saving you a write up/time, GG, TA PS, however, DaiS may want to answer with her prospective from UK.

To: Edderd who wrote (9682)	6/16/1998 1:15:00 AM
From: VLAD	Read Replies (1) \| Respond to of 23519

Edderd, Here is a brief reminder of a few minor incidents that resulted in a label recall/change of MUSE. -This is the retyped text of a letter from Vivus, Inc. Contact the company for a copy of any referenced enclosures. -------------------------------------------------------------------------------- NEW PRESCRIBING INFORMATION Dear : The VIVUS Medical Services Department would like to notify you of important changes to the prescribing information for MUSE (alprostadil), which is indicated for the treatment of erectile dysfunction. VIVUS has made changes to the Package Insert and Patient Package Insert to clarify prescribing information and to reflect the marketing experience obtained since the launch of MUSE in December, 1996. Our current prescribing information contains the following warning: "Because of the potential for symptomatic hypotension and syncope, which occurred in 3% and 0.4%, respectively, of patients during in-clinic dosing, MUSE titration should be carried out under medical supervision." Our Medical Services Department has received three reports of patients who were discharged from clinic after MUSE administration and had syncopal episodes shortly thereafter. We have therefore provided additional guidance in the warning section of our package Insert: "During post-marketing surveillance syncope occurring within one hour of administration has been reported. Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after MUSE administration." VIVUS would also like to remind physicians that dose titration should be administered under medical supervision to test the patient's responsiveness to MUSE, to demonstrate proper administration technique, and to monitor for evidence of hypotension. The lowest effective dose of MUSE should be prescribed. The revised Package Insert also mentions a potentially important drug-drug interaction (see new text in italics): "Because there are low or undetectable (<2 picograms/mL) amounts of alprostadil found in the peripheral venous circulation following MUSE administration, systemic drug-drug interactions with MUSE are unlikely. Although formal studies have not been conducted, the concomitant use of MUSE and anti-hypertensive medications may increase the risk of hypotension. It is therefore advised that caution be used in the administration of MUSE to individuals on anti-hypertensive medication. In addition, the presence of medications in the circulation that attenuate erectile function may influence the response to MUSE." The revised Package Insert also includes text to clarify that while symptomatic lowering of blood pressure was observed in 3% of patients, some lowering of blood pressure may occur without symptoms. The new language in the "adverse reactions, in-clinic titration" section appears below (see new text in italics): "Symptomatic lowering of blood pressure (hypotension) occurred in 3% of patients; in addition, some lowering of blood pressure may occur without symptoms. Dizziness was reported in 4% of patients. Syncope (fainting) was reported by 0.4% of patients." We have also added a new paragraph at the end of the "adverse reactions, home treatment" section: "Other drug-related side effects observed during in-clinic titration and home treatment include swelling of leg veins, leg pain, perineal pain, and rapid pulse, each occurring in <2% of patients." VIVUS has revised its Patient Package Insert to be consistent with the above information. Since the introduction of MUSE, the product has been prescribed to more that 300,000 patients in the US. VIVUS is committed to keeping healthcare professionals and patients informed of the latest prescribing information to ensure the safe and effective use of our product. Please feel free to contact us at 1-888-345-6873. Enclosed you will please find the updated Package Insert and the Patient Package Insert. VIVUS encourages you to review these carefully. Sincerely yours, Alfred P. Spivack, MD Director Medical Services Enclosures -------------------------------------------------------------------------------- VIVUS, Inc. 545 Middlefield Road Menlo Park, CA 94025 Tel 1-888-345-6873 Fax 1-703-449-0520 www.vivus.com Last modified on Sunday, 17-May-98 19:07:09. -------------------------------------------------------------------------------- PharmInfoNet HomePage Ed, It seemed like the FDA was real concerned about a few guys fainting and also wanted a few more side effects mentioned. Now what about Viagra? I think at least a WARNING of the dangers of Viagra and other hypotensive drugs will have to be eventually issued. Nitro is so hypotensive that men taking it and Viagra die. Viagra and high blood pressure meds CAN at least create a fainting spell which can lead to eg a car accident etc... IMO there is a large can of worms yet to be opened. The Viagra issue is a time bomb waiting to detonate--not only based on physiological side effects but also in regards to social/ethical issues.